Search Result
Results for "
adjunct
" in MedChemExpress (MCE) Product Catalog:
5
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-A0166
-
|
MK0791
|
Bacterial
Antibiotic
|
Infection
|
|
Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct .
|
-
-
- HY-A0166A
-
|
MK0791 sodium
|
Bacterial
Antibiotic
|
Infection
|
|
Cilastatin sodium (MK0791 sodium) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin sodium inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin sodium is an antibacterial adjunct .
|
-
-
- HY-114703
-
-
-
- HY-B2156
-
|
Vitamin K2(MK-4); Menaquinone K4
|
Endogenous Metabolite
|
Cancer
|
|
Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
|
-
-
- HY-A0166S
-
|
MK0791-15N,d3
|
Bacterial
Antibiotic
|
Infection
|
|
Cilastatin- 15N,d3 is a 15N-labeled and deuterium labeled Cilastatin. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].
|
-
-
- HY-B1475
-
|
Octatropine bromide
|
mAChR
|
Neurological Disease
Metabolic Disease
|
|
Anisotropine (Octatropine) bromide is an orally active anticholinergic muscarinic antagonist. Anisotropine bromide can inhibit gastric acid secretion and is used as an adjunct to peptic ulcers .
|
-
-
- HY-A0042
-
|
CGP 33101; E 2080; RUF 331
|
Others
|
Neurological Disease
|
|
Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
|
-
-
- HY-A0166R
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Cilastatin (Standard) is the analytical standard of Cilastatin. This product is intended for research and analytical applications. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct .
|
-
-
- HY-B2156S1
-
|
Vitamin K2(MK-4)-13C6; Menaquinone K4-13C6
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cancer
|
|
Menaquinone-4- 13C6 is the 13C-labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
|
-
-
- HY-B2156R
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Menaquinone-4 (Standard) is the analytical standard of Menaquinone-4. This product is intended for research and analytical applications. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
|
-
-
- HY-106450
-
|
MRE-0470; WRC 0470
|
Adenosine Receptor
|
Cardiovascular Disease
|
|
Binodenoson (MRE-0470) is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging .
|
-
-
- HY-147263
-
|
CC-11050
|
Phosphodiesterase (PDE)
|
Infection
Inflammation/Immunology
|
|
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .
|
-
-
- HY-A0042S
-
|
CGP 33101-d2; E 2080-d2; RUF 331-d2
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide. Rufinamide (E 2080) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
|
-
-
- HY-14263
-
|
Propericiazine; RP 8909
|
Dopamine Receptor
|
Neurological Disease
|
|
Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis . Pericyazine is a selective D2-dopamine receptor antagonist . Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects .
|
-
-
- HY-A0042S1
-
|
CGP 33101-15N,d2; E 2080-15N,d2; RUF 331-15N,d2
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
Rufinamide- 15N,d2 is the deuterium and 15N labeled Rufinamide[1]. Rufinamide is a new antiepileptic agent that differs structurally from other antiepileptic agents and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS)[2][3].
|
-
-
- HY-B2156S
-
|
Vitamin K2(MK-4)-d7; Menaquinone K4-d7
|
Endogenous Metabolite
|
Cancer
|
|
Menaquinone-4-d7 (Vitamin K2(MK-4)-d7) is the deuterium labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
|
-
-
- HY-B1283
-
|
|
iGluR
|
Neurological Disease
|
|
Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or as an adjunctive treatment of painful muscle spasm .
|
-
-
- HY-A0248
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .
|
-
-
- HY-P99551
-
|
KBSA301; AR-301
|
Antibiotic
|
Infection
|
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
|
-
-
- HY-B1116A
-
|
(-)-Metaraminol; (-)-erythro-Metaraminol; (-)-m-Hydroxynorephedrine
|
Others
|
Neurological Disease
|
|
Metaraminol ((-)-Metaraminol) is a sympathomimetic compound with activity that acts primarily at alpha-1 adrenergic receptors. Metaraminol is used to inhibit hypotension due to vasodilation, particularly in critically ill patients who do not respond well to volume resuscitation. Metaraminol may also be used as an adjunct to help improve cardiac contractility. The use of metaraminol may be supported by less evidence, but its effectiveness in specific situations remains of interest .
|
-
-
- HY-A0248R
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Polymyxin B (Sulfate) (Standard) is the analytical standard of Polymyxin B (Sulfate). This product is intended for research and analytical applications. Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .
|
-
-
-
HY-L192
-
|
|
69 compounds
|
|
Dietary supplement, also known as nutritional supplement or food supplement, include dietary components such as vitamins, minerals, and amino acids. The unique value of dietary supplement is particularly significant in the post-pandemic era. Compared to traditional medication, dietary supplement is often more readily accepted by the public due to their higher safety profile and the natural origin. By orally supplementing essential nutrients and bioactive substances, dietary supplement can help to enhance the body's health level and reduce the risk of diseases. For certain chronic conditions, proper dietary supplement can also serve as a powerful adjunct to conventional medical treatment, enhancing the effectiveness of medication.
MCE has included 69 dietary supplements, whose ingredients are all derived from the official lists published by authoritative organizations such as the FDA, EFSA, NMPA, etc. These compounds can be utilized in the development of health food products and for the mechanistic research of certain chronic diseases.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-A0248
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .
|
-
- HY-A0248R
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Polymyxin B (Sulfate) (Standard) is the analytical standard of Polymyxin B (Sulfate). This product is intended for research and analytical applications. Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99551
-
|
KBSA301; AR-301
|
Antibiotic
|
Infection
|
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-A0166S
-
|
|
|
Cilastatin- 15N,d3 is a 15N-labeled and deuterium labeled Cilastatin. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].
|
-
-
- HY-B2156S1
-
|
|
|
Menaquinone-4- 13C6 is the 13C-labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
|
-
-
- HY-A0042S
-
|
|
|
Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide. Rufinamide (E 2080) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
|
-
-
- HY-A0042S1
-
|
|
|
Rufinamide- 15N,d2 is the deuterium and 15N labeled Rufinamide[1]. Rufinamide is a new antiepileptic agent that differs structurally from other antiepileptic agents and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS)[2][3].
|
-
-
- HY-B2156S
-
|
|
|
Menaquinone-4-d7 (Vitamin K2(MK-4)-d7) is the deuterium labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
